- Home
- ASB vs SRRK Comparison
ASB vs SRRK Comparison
Compare ASB & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASB
- SRRK
- Stock Information
- Founded
- ASB 1861
- SRRK 2012
- Country
- ASB United States
- SRRK United States
- Employees
- ASB N/A
- SRRK N/A
- Industry
- ASB Major Banks
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASB Finance
- SRRK Health Care
- Exchange
- ASB Nasdaq
- SRRK Nasdaq
- Market Cap
- ASB 3.9B
- SRRK 4.2B
- IPO Year
- ASB N/A
- SRRK 2018
- Fundamental
- Price
- ASB $24.44
- SRRK $37.70
- Analyst Decision
- ASB Hold
- SRRK Strong Buy
- Analyst Count
- ASB 9
- SRRK 7
- Target Price
- ASB $27.11
- SRRK $40.43
- AVG Volume (30 Days)
- ASB 1.5M
- SRRK 793.4K
- Earning Date
- ASB 01-23-2025
- SRRK 02-27-2025
- Dividend Yield
- ASB 3.76%
- SRRK N/A
- EPS Growth
- ASB N/A
- SRRK N/A
- EPS
- ASB 0.72
- SRRK N/A
- Revenue
- ASB $952,855,000.00
- SRRK N/A
- Revenue This Year
- ASB N/A
- SRRK N/A
- Revenue Next Year
- ASB $5.85
- SRRK N/A
- P/E Ratio
- ASB $33.94
- SRRK N/A
- Revenue Growth
- ASB N/A
- SRRK N/A
- 52 Week Low
- ASB $19.76
- SRRK $6.76
- 52 Week High
- ASB $28.18
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- ASB 43.77
- SRRK 41.93
- Support Level
- ASB $24.62
- SRRK $35.35
- Resistance Level
- ASB $25.60
- SRRK $38.61
- Average True Range (ATR)
- ASB 0.58
- SRRK 1.80
- MACD
- ASB -0.04
- SRRK -0.16
- Stochastic Oscillator
- ASB 24.84
- SRRK 34.20
About ASB Associated Banc-Corp
Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.